Eagle Asset Management Inc. Sells 15,460 Shares of Disc Medicine, Inc. (NASDAQ:IRON)

Eagle Asset Management Inc. lowered its stake in Disc Medicine, Inc. (NASDAQ:IRON) by 15.7% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 83,215 shares of the company’s stock after selling 15,460 shares during the quarter. Eagle Asset Management Inc.’s holdings in Disc Medicine were worth $4,089,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Amalgamated Bank raised its stake in shares of Disc Medicine by 76.9% in the second quarter. Amalgamated Bank now owns 568 shares of the company’s stock worth $26,000 after buying an additional 247 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in Disc Medicine by 45.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock valued at $54,000 after purchasing an additional 337 shares during the period. Quest Partners LLC bought a new stake in Disc Medicine during the 3rd quarter valued at approximately $131,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Disc Medicine during the 2nd quarter valued at approximately $129,000. Finally, ProShare Advisors LLC bought a new stake in Disc Medicine during the 1st quarter valued at approximately $211,000. Institutional investors own 83.70% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on IRON. Raymond James raised Disc Medicine from an “outperform” rating to a “strong-buy” rating and lifted their target price for the company from $66.00 to $110.00 in a research note on Monday, November 4th. Wedbush reissued an “outperform” rating and set a $83.00 target price (up previously from $75.00) on shares of Disc Medicine in a research note on Tuesday, November 12th. Wells Fargo & Company assumed coverage on Disc Medicine in a research note on Thursday, August 22nd. They set an “overweight” rating and a $75.00 target price on the stock. HC Wainwright lifted their price objective on Disc Medicine from $70.00 to $118.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, Morgan Stanley raised Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price objective on the stock in a research note on Tuesday, November 5th. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $85.80.

Disc Medicine Stock Up 2.3 %

IRON opened at $64.96 on Monday. The business has a fifty day moving average of $52.44 and a 200 day moving average of $46.33. Disc Medicine, Inc. has a 52-week low of $25.60 and a 52-week high of $77.60. The stock has a market cap of $1.93 billion, a P/E ratio of -16.32 and a beta of 0.60.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.89) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.15. Equities analysts anticipate that Disc Medicine, Inc. will post -4.05 EPS for the current fiscal year.

Insider Activity at Disc Medicine

In other Disc Medicine news, insider William Jacob Savage sold 9,158 shares of Disc Medicine stock in a transaction on Friday, November 15th. The stock was sold at an average price of $59.64, for a total transaction of $546,183.12. Following the completion of the sale, the insider now directly owns 40,405 shares of the company’s stock, valued at $2,409,754.20. The trade was a 18.48 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director William Richard White sold 7,136 shares of Disc Medicine stock in a transaction on Monday, November 4th. The shares were sold at an average price of $58.61, for a total value of $418,240.96. The disclosure for this sale can be found here. Insiders sold a total of 16,696 shares of company stock worth $984,058 in the last quarter. 4.24% of the stock is owned by company insiders.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.